CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
MAP0010 low dose +3 moredrug
Likely dose
Budesonide inhalation suspension 0.25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00554970
NCT00554970Phase 2Completed
CompareCT.gov

A Randomized, Open Label, Active-Controlled, 4-Treatment, 2-Period, 2 Parallel Block Crossover Pharmacokinetic and Safety Study of 2 Doses of MAP0010 in Adult Asthmatics

Allergan·interventional·Posted Nov 7, 2007·Updated Jan 9, 2014

In Brief

A Phase 2 clinical trial evaluating MAP0010 low dose, MAP0010 high dose, and 2 other interventions for Asthma. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the blood levels of two doses of MAP0010 (a corticosteroid) and two doses of an approved corticosteroid in adult asthma and safety with twice daily dosing over 7 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
CollaboratorsMAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 7, 2007
Enrollment StartNov 1, 2007
Primary CompletionJan 1, 2008
Study CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 18.7 years ago

Interventions

MAP0010 low dosedrug

a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol

MAP0010 high dosedrug

a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol

Budesonide inhalation suspension 0.25mgdrug

a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol

Budesonide inhalation suspension 0.5mgdrug

a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol